AUR PRO
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of Michigan Comprehensive Cancer Center,  University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 022
A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Baylor College of Medicine, Dana-Farber/Harvard Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, University of California San Francisco, University of Michigan Comprehensive Cancer Center, University of North Carolina at Chapel Hill, University of Pittsburgh Cancer Institute

Relevant Publications/Presentations: 2019 SABCS Poster; 2019 Clin Breast Cancer Publication; 2018 JCO Publication; 2017 ASCO Talk; 2016 JCO Publication; 2014 ASCO Poster Highlights; 2012 SABCS Poster

TBCRC 034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy

Dana-Farber/Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Indiana University Simon Cancer Center, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of North Carolina at Chapel Hill / Lineberger Cancer Center, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/Fred Hutchinson Cancer Center

Relevant Publications/Presentations: 2020 Ann Surg Oncol Publication; 2019 SSO Talk

TBCRC 037
A Trial of Endocrine Response in Patients with Invasive Lobular Carcinoma

Baylor College of Medicine, Duke University Medical Cancer Center, Georgetown University, Indiana University Simon Cancer Center, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill / Lineberger Cancer Center, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/Fred Hutchinson Cancer Center

Relevant Publications/Presentations: 2015 SABCS Poster

TBCRC 039
Ruxolitinib with Preoperative Chemotherrapy for Triple Negative Inflammatory Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, University of Pennsylvania

Relevant Publications/Presentations: 2017 SABCS Poster

TBCRC 042
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

Baylor College of Medicine, Indiana University Simon Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 044
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of Pittsburgh Cancer Institute, Vanderbilt University

Relevant Publications/Presentations: 2020 SABCS Poster; 2020 ASCO Poster; 2019 SABCS Poster; 2018 SABCS Poster; 2018 ASCO Poster; 2017 SABCS Poster

TBCRC 045
The “Aviator” Study: Trastuzumab and Vinorelbine with Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Indiana University Simon Cancer Center, Johns Hopkins University, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 048
Olaparib in Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California San Francisco, University of Chicago Medical Center, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2020 ASCO Talk; 2020 JCO Publication

TBCRC 049
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, MD Anderson Cancer Center, University of Alabama at Birmingham, University of California San Francisco, University of Chicago Medical Center, University of Michigan Comprehensive Cancer Center, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2020 SNO Poster; 2019 SABCS Poster

TBCRC 050
Niraparib in Combination with Trastuzumab in Metastatic HER2+ Breast Cancer

Montefiore Medical Center,  University of Alabama at Birmingham, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 051
Estradiol in Treating Patients with ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Georgetown University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 052
MARGetuximab Or Trastuzumab (MARGOT)

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Georgetown University, Montefiore Medical Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 053
Pre-operative Pembrolizumab + Radiation Therapy in Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Johns Hopkins University, University of Michigan Comprehensive Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh Cancer Institute, University of North Carolina at Chapel Hill, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 054
Exercise Treatment with Standard Therapy for Metastatic Breast Cancer

Montefiore Cancer Center, Memorial Sloan Kettering Cancer Center

TBCRC 056
Niraparib + TSR042 in BRCA Mutated Breast Cancer

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, University of Michigan Comprehensive Cancer Center, Montefiore Medical Center, University of Pittsburgh Cancer Institute, University of North Carolina at Chapel Hill, Vanderbilt University